Shares of Aerie Pharmaceuticals Inc. (NASDAQ:AERI) have received an average rating of “Buy” from the ten research firms that are currently covering the company. One analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $54.89.

Several equities research analysts have weighed in on the stock. Zacks Investment Research raised shares of Aerie Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $20.00 price target for the company in a research report on Monday, July 4th. Stifel Nicolaus increased their price target on shares of Aerie Pharmaceuticals from $50.00 to $55.00 and gave the company a “buy” rating in a research report on Thursday. Brean Capital reissued a “buy” rating and set a $63.00 price target on shares of Aerie Pharmaceuticals in a research report on Thursday. Royal Bank Of Canada increased their price target on shares of Aerie Pharmaceuticals from $51.00 to $55.00 and gave the company an “outperform” rating in a research report on Thursday, September 15th. Finally, Canaccord Genuity set a $50.00 price target on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, September 14th.

In other Aerie Pharmaceuticals news, major shareholder Foresite Capital Fund Ii, L.P. purchased 250,000 shares of the stock in a transaction that occurred on Friday, July 22nd. The stock was bought at an average cost of $17.50 per share, with a total value of $4,375,000.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 8.77% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp boosted its position in shares of Aerie Pharmaceuticals by 1.0% in the second quarter. Bank of New York Mellon Corp now owns 132,146 shares of the company’s stock worth $2,325,000 after buying an additional 1,312 shares during the period. Tocqueville Asset Management L.P. boosted its position in shares of Aerie Pharmaceuticals by 1.7% in the second quarter. Tocqueville Asset Management L.P. now owns 42,300 shares of the company’s stock worth $744,000 after buying an additional 725 shares during the period. Northpointe Capital LLC boosted its position in shares of Aerie Pharmaceuticals by 64.9% in the second quarter. Northpointe Capital LLC now owns 481,769 shares of the company’s stock worth $8,479,000 after buying an additional 189,629 shares during the period. Rice Hall James & Associates LLC boosted its position in shares of Aerie Pharmaceuticals by 1.2% in the second quarter. Rice Hall James & Associates LLC now owns 158,932 shares of the company’s stock worth $2,797,000 after buying an additional 1,909 shares during the period. Finally, Essex Investment Management Co. LLC boosted its position in shares of Aerie Pharmaceuticals by 472.3% in the second quarter. Essex Investment Management Co. LLC now owns 107,700 shares of the company’s stock worth $1,896,000 after buying an additional 88,880 shares during the period. 95.22% of the stock is owned by institutional investors.

Aerie Pharmaceuticals (NASDAQ:AERI) traded up 3.08% during trading on Thursday, reaching $40.47. 830,968 shares of the company traded hands. The firm’s market capitalization is $1.13 billion. Aerie Pharmaceuticals has a 12-month low of $10.82 and a 12-month high of $41.72. The firm’s 50 day moving average price is $27.34 and its 200 day moving average price is $19.13.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its earnings results on Wednesday, August 3rd. The company reported ($0.72) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.74) by $0.02. Equities research analysts expect that Aerie Pharmaceuticals will post ($2.80) earnings per share for the current year.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.

5 Day Chart for NASDAQ:AERI

Receive News & Stock Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.